Holen Sie sich die Stockscreener-App
15.30
4.76%
0.695
Handel nachbörslich:
14.97
-0.33
-2.16%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
(TVTX) On The My Stocks Page - news.stocktradersdaily.com
Rhumbline Advisers Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
What is HC Wainwright’s Estimate for TVTX Q2 Earnings? - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Eagle-Tribune
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day - Black Hills Pioneer
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Leerink Partnrs Has Negative Outlook for TVTX Q4 Earnings - Defense World
Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles - Investing.com Canada
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - Defense World
Travere Therapeutics (NASDAQ:TVTX) Stock Rating Upgraded by HC Wainwright - Defense World
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2025 - BioSpace
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Travere Therapeutics Inc (TVTX) Has Recovered 53.17% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - WV News
Travere Therapeutics (TVTX) Price Target Lowered by Citigroup | - GuruFocus
Citi Adjusts Price Target and Maintains Buy Rating on Travere Th - GuruFocus
Travere Therapeutics (TVTX) Price Target Lowered by Citigroup | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Receives Buy Rating from HC Wainwrig - GuruFocus
Travere Therapeutics (TVTX) Receives Buy Rating from HC Wainwright & Co. | TVTX Stock News - GuruFocus
7 Analysts Assess Travere Therapeutics: What You Need To Know - Nasdaq
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference | TVTX Stock News - GuruFocus
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference - Eagle-Tribune
H.C. Wainwright Initiates Coverage on Travere Therapeutics (TVTX) with Optimistic Outlook | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Sees Price Target Adjustment with Ne - GuruFocus
Citi Adjusts Price Target and Maintains Buy Rating on Travere Therapeutics (TVTX) | TVTX Stock News - GuruFocus
Travere Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Travere Therapeutics Launches "Play It Forward" Campaign to Cele - GuruFocus
Grammy-Winning Producer Teams Up With Patient Artist for First-Ever FSGS Awareness Campaign - Stock Titan
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by California State Teachers Retirement System - Defense World
Wellington Management Group LLP Invests $583,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Squarepoint Ops LLC Sells 11,006 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Transcript : Travere Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress - BioSpace
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress | TVTX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect - ACCESS Newswire
2025-06-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out | NDAQ:TVTX | Press Release - Stockhouse
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
TVTX Investor Notice: Levi & Korsinsky Investigates Travere Therapeutics, Inc. for Securities Law Violations - Louisiana First News
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - The Malaysian Reserve
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
3.56%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):